THERAPY DOSSIER · th-4752b612fcf6

Ginkgo biloba extract 761 (EGb761)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 7

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02181972 ↗PHASE3completed

AGENT-level surrogate: Ginkgo biloba film-coated tablets and cognition in middle-aged cognitively intact adults

Healthy

Enrolment: 120 · Results not recorded

NCT00814346 ↗PHASE2completed

Effect of oral EGb761 on brain glucose metabolism in elderly with memory complaint or mild Alzheimer's disease

Alzheimer's Disease · Cognitive Impairment

Enrolment: 49 · Results not recorded

NCT01006421 ↗Phase not recordedunknown

AGENT-level surrogate: oral Ginkgo biloba and narrow band UVB in vitiligo

Vitiligo

Enrolment: 160 · Results not recorded

NCT04492241 ↗NAunknown

AGENT-level surrogate: Ginkgo leaf extract and Armillariella mellea oral solution in motoric cognitive risk syndrome

Motoric Cognitive Risk Syndrome · Mild Cognitive Impairment

Enrolment: 800 · Results not recorded

NCT05591144 ↗NAcompleted

AGENT-level surrogate: short-term oral prednisone with Ginkgo biloba extract in acute subjective tinnitus

Tinnitus, Subjective

Enrolment: 146 · Results not recorded

NCT03090516 ↗PHASE2|PHASE3unknown

AGENT-level surrogate: Ginkgo biloba dispersible tablets for cognition in mild to moderate Alzheimer's disease

Alzheimer's Disease

Enrolment: 240 · Results not recorded

NCT06403787 ↗PHASE2|PHASE3completed

AGENT-level surrogate: aerobic training and Ginkgo biloba extract on plasma LDL and HDL in HIV positive patients

Human Immunodeficiency Virus

Enrolment: 28 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26481704 ↗2015Reported benefit

EGb761 improves histological and functional recovery in rats with acute spinal cord contusion injury.

RatSpinal cord injuryContusionSprague-DawleyFemalen = N=30 rats randomised into three groups (sham-operated, sali…Administered during the acute phase after spinal cord injury

Model: Acute standardised spinal cord contusion injury

EGb761-treated rats had significantly better BBB scores at 14 days post injury (P<0.05) but not at 1, 3 or 7 days, together with increased stride length, decreased stride width and less toe dragging at 14 days. Necrosis area was reduced and apoptotic cell numbers were significantly lower at 7 days…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…